Brand Name : Sorafenat
Available Dose : 200 mg
Composition : Sorafenib Tosylate
Manufactured by : Natco Pharma Ltd.
Dosage Form : Tablets
Packing : Pack of 120 Tablets
Sorafenat belongs to a class of multi kinase inhibitors, the main ingredient which is used as sorafenib. It is not used as curable medicine but Sorafenat is used to reduce the growth rate of cancer cells by barrier the actions of an aberrant protein signal transduction helps to develop the cancer cells. Sorafenat is mechanism by depleting the blood supply to the cancer cells and stopa their division and production.
• The Sorafenat Tablets usual dose is 400 mg (2 x 200 mg tablets)
• Sorafenat administrated twice daily on empty stomach (at least 1 hour before or 2 hours after a meal).
• The therapy should continue untill the patient is not clinically benefiting from the treatment.
Sorafenat abolish the surface of cell and intracellular kinase to lag the development of tumor cells. Sorafenat work as a biological treatment which is a inhibitor of protein kinase which is an enzyme ( chemical messenger). This enzyme enhance grow of tumor cells.
Sorafenat which will also work as multi kinase inhibitor, Since Sorafenat stops the protein kinase. It has two way actions,
1. Sorafenat will aim the protein which normally help to develop the malignant cells.
2. Sorafenat helps to block cancer cells forming from new blood vessels.
Sorafenat tablet when compared to oral solution the mean bioavailability is 38-49% after absorption. The time to high plasma level of Sorafenat is 3hrs. Therefore Sorafenat is administrated without food.
The drug Sorafenat has human plasma protein bounding is 99.5%
In liver CYP3A4, Sorafenat go through metabolism of oxidative and in glucuronidation by UGT1A9. Sorafenat has totally 8 metabolite are found in which 5 metabolite present in serum.
In oral administration, the total dose excreted 96% within 14 days, and elimination of dose via feces 77% and dose in urine 19% as glucuronidated.
Sorafenat interaction with carbamazepine + dexamethasone + Phenobarbital + phenytoin + rifamipicin leads to reduce in Sorafenib plasma concentration. Sorafenat interaction with doxorubicin and irinotecan will increase the plasma concentration.
The patients is contraindicated to hypersensitivity reaction then avoid using Sorafenat tablet Carboplatin and paclitaxel interaction with Sorafenat will cause to squamous cell lung cancer.
It is unknown that this medicine passes into breast milk or could harm a new born baby. Avoid using of Sorafenat medication, if your breast feeding.
Stored at 25℃ Place in cool and dry place and protect from light and heat. Dispense in its original container and close it tightly. Sorafenat should keep away from children.
To confirm the Using of Sorafenat medicine is safe for the patient , Inform the doctor if you have any of these other conditions:
• kidney or liver problems other than cancer
• high BP
• Cardiac problems
• a history of stroke
If you are allergic to Sorafenib (the active ingredients)
SORAFENIB SIDE EFFECTS
Common Sorafenib Side Effects: mouth dryness ; throat soreness ; Tiredness :Acne ; Dry skin ; Nausea ; Itching or rash skin ; Vomiting, ; Diarrhea ; Patchy hair thinning, ; decreased appetite ; Stomach pain ; etc.
Serious Side Effects : Chest heavy feeling ; Sudden weakness ; Increased blood pressure ; Bloody stools ; Coughing up blood / vomit ; fast heart rate ; low concentration ;; dermatology problem; jaundice etc.
Mechanism of action: Sorafenib is an oral anti-cancer drugs, and also an inhibitor of various protein kinases, as such as VEGFR, PDGFR and Raf family kinases, because of usage in different kinases it is commonly known for multikinase enzyme inhibitor that decreases cell proliferation in vitro, researchers still made to improve sorafenib mechanism of action to behave as effective inhibitor.